Mixed Lineage Kinase

MLKs

Mixed Lineage Kinase

Related Products

Mixed lineage kinases (MLKs) are mitogen activated protein kinase kinase kinases (MAPKKKs) with features of both serine-threonine and tyrosine kinases that regulate the c-Jun N-terminal kinase (JNK) mitogen activated protein kinase (MAPK) signaling cascade, and also regulate p38 and extracellular signal-regulated kinase (ERK).

MLK3 (MAP3K11) is the most widely expressed MLK family member, and is expressed in neurons (as well as other cell types). At the cellular level, MLK3 is activated by stress, including reactive oxygen species, ceramide, and TNFα. At the molecular level, it is activated by Cdc42 and Rac, which interact with MLK3, and can cause it to dimerize via a leucine zipper interface, resulting in autophosphorylation and enzyme activation.

Mixed Lineage Kinase Related Products (30)
Antibodies (3)

By Effects:	Inhibitors (23) Degrader (1) Activators (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-100573

Necrosulfonamide	Inhibitor	99.47%
Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis.

HY-112292

GW806742X	Inhibitor	99.91%
GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X has activity against VEGFR2/KDR/Flk-1 (IC₅₀=2 nM). GW806742X retards MLKL membrane translocation and inhibits necroptosis.

HY-144828

RIP1/RIP3/MLKL activator 1	Activator
RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability.

HY-15323

PRT062607 Hydrochloride	Inhibitor	98.07%
PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC₅₀: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models.

HY-12599

URMC-099	Inhibitor	99.34%
URMC-099 is an orally bioavailable and potent mixed lineage kinase type 3 (MLK3) (IC₅₀=14 nM) inhibitor with with excellent blood-brain barrier penetration properties.

HY-168026

CEP1347-VHL-02
CEP1347-VHL-02 is a PROTAC targeting MLK3. CEP1347-VHL-02 consists of PROTAC target protein ligand CEP-1347 (HY-10412) (red part), E3 ubiquitin ligase ligand (S,R,S)-AHPC-Me (HY-112078) (blue part) and PROTAC Linker Amino-PEG3-CH2COOH (HY-140189) (black part), of which the target protein ligand activity control is CEP-1347-acid (HY-168027), and the conjugate of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 (HY-131387)^{[1]^.}

HY-169072

PROTAC MLKL Degrader-2
PROTAC MLKL Degrader-2 (compound MP-1) is a PROTAC targeting MLKL (Mixed Lineage Kinase). PROTAC MLKL Degrader-2 is composed of PROTAC target protein ligand PROTAC MLKL Degrader-2 (HY-169072) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part) and PROTAC Linker N-Methylpiperazine (HY-78871) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074)^{[1]^.}

HY-101524

TC13172	Inhibitor	98.93%
TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC₅₀ value of 2 nM for HT-29 cells.

HY-112292A

GW806742X hydrochloride	Inhibitor	98.77%
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a K_d of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2/KDR/Flk-1 (IC₅₀=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.

HY-111351

MLK-IN-1	Inhibitor	99.06%
MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1.

HY-148907

CS640	Inhibitor	99.43%
CS640 is a selective inhibitor of calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC₅₀ values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC₅₀ values of 6 and 10 μM, respectively.

HY-10412

CEP-1347	Inhibitor	98.50%
CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53.

HY-148365

NecroIr1	Activator	98.02%
NecroIr1 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and Mixed Lineage Kinase (MLKL), and regulates CDK/cdk4.html” class=”link-product” target=”_blank”>CDK4 expression.

HY-149258

KWCN-41	Inhibitor	99.83%
KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC₅₀ value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis. KWCN-41 also has anti-inflammatory effects.

HY-156119

MLKL-IN-6	Inhibitor	98.57%
MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects.

HY-148366

NecroIr2	Activator	98.99%
NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression.

HY-141889

MLKL-IN-2	Inhibitor	99.83%
MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i).

HY-156591

PROTAC MLKL Degrader-1	Degrader	99.76%
PROTAC MLKL Degrader-1 (Compound 36) is a PROTAC degrader of MLKL, with a D_max ＞90%. PROTAC MLKL Degrader-1 contains modified CRBN ligands, linker and Lenalidomide (HY-A0003)-linker fragments. PROTAC MLKL Degrader-1 abrogates cell death in a TSZ model of necroptosis.

HY-15324

PRT062607 acetate	Inhibitor	99.83%
PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC₅₀: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models..

HY-100573S

Necrosulfonamide-d₄	Inhibitor	99.26%
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Mixed Lineage Kinase

Mixed Lineage Kinase

Mixed Lineage Kinase Related Products (30)

Antibodies (3)

Mixed Lineage Kinase Related Products (30):